Cancer's gene-determined 'immune landscape' dictates progression of prostate tumorsJanuary 12, 2018
BOSTON - The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.
Now, researchers at the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) have demonstrated that genetic variations driving prostate cancer determine the composition of the immune cells that have been found to infiltrate primary prostate tumors. These immune cells, in turn, dictate tumor progression and response to treatment. The data, published in Nature Medicine, suggest that profiling patients' tumors based on this new information could lead to more successful clinical trials and tailored therapies for patients.
"We observed that specific genetic events resulted in striking differences in the composition of immune cells present in and around the tumor - results with important therapeutic implications," said senior author Pier Paolo Pandolfi, MD, PhD, Director of the Cancer Center and Cancer Research Institute at BIDMC. "Our data may be especially relevant for tailoring immunological therapies and for identifying responsive-patient population."
The third leading cause of cancer-related death in U.S. men, prostate cancer, is linked to a number of diverse genetic mutations that drive the disease. For example, the loss of the tumor suppressor gene PTEN is a frequent event in prostate cancer and is well known to promote the disease in combinations with a plethora of other mutations. Researchers also know that the tumor's microenvironment - the blood vessels, immune cells, signaling molecules and other factors that surround the tumor - plays an important role in tumor progression and response to therapy.
Pandolfi's team - including lead author, Marco Bezzi, a post-doctoral fellow in Pandolfi's lab - engineered mice models to represent four distinct known genetic variations of human prostate cancer. The models lacked either Pten alone or in combination with other genetic alterations known to drive the disease. When the team analyzed the tumors from these mice, they saw profound differences in the types and relative numbers of the immune cells that had accumulated in and around the tumor, what they call the tumors' "immune landscape".
For example, specific immune landscapes tumors from the genetic model lacking both Pten and the tumor suppressor gene called Trp53 demonstrated an increased accumulation of myeloid cells, the immune cells that mediate immunosuppression. In stark contrast, tumors from the genetic model lacking Pten and a different tumor suppressor gene called PML lacked intratumoral immune infiltration; that is, the researchers observed no immune cells at all in these tumors, which the scientists dubbed "cold," or "immune-deserts." All four mouse models analyzed presented very distinctive immune landscapes and these differences were maintained and exacerbated over time.
The research team also demonstrated that these differences in immune cell composition were directly dictated by the tumors themselves because of their genetic variations. Different tumors, they observed, secreted distinct chemical attractants, which in turn recruited - or didn't recruit, in the case of the immune-desert tumors - different immune cell types into the tumor. Pandolfi and colleagues further demonstrated that these differences hold true in human prostate cancer. Critically, the immune cells recruited to the tumors were found to be essential in supporting the growth and progression of these tumors.
"We observed that when present, these infiltrating immune cells were required for the tumor to thrive and found therapies to block their recruitment to be effective," said Bezzi. "On the other hand, the cancer genotype characterized by the so-called 'immune desert' phenotype, did not respond to such therapies. On this basis, we can predict the tumor response to immunotherapies and tailor treatment modalities to effectively impact tumors that are otherwise extremely aggressive," he said.
Thus, because immune cells interact with and also affect tumor response to therapy, these findings may be especially relevant for the development of more precise and effective combinations of immunotherapies and targeted therapies on the basis of the cancer genetic makeup.
"These profound differences in immunological landscapes among various cancer genotypes further highlight the need to thoroughly investigate and integrate genotypes and immune-phenotypes in the context of exploratory cancer treatments in both preclinical and clinical settings," said Pandolfi.
This work was funded by the National Institutes of Health (R01 CA102142 and R35 CA197529) and by a Jane Coffin Childs Postdoctoral Fellowship.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox.
For more information, visit http://www.bidmc.org.
Beth Israel Deaconess Medical Center
Related Prostate Cancer Articles:
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
For the first time ever, researchers have differentiated the risks of developing indolent or aggressive prostate cancer in men with a family history of the disease.
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Primary care providers are put in a difficult position when screening their male patients for prostate cancer -- some guidelines suggest that testing the general population lacks evidence whereas others state that it is appropriate in certain patients.
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
The radiation oncology team at UH Seidman Cancer Center in Cleveland performed the first-ever prostate cancer treatment April 3 using a newly-approved device -- SpaceOAR which enhances the efficacy of radiation treatment by protecting organs surrounding the prostate.
Related Prostate Cancer Reading:
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer
by Patrick C. Walsh (Author), Janet Farrar Worthington (Author)
Now updated and revised, the definitive book on surviving prostate cancer from the world's leading authority on the prostate.
Each year, more than 230,000 men are diagnosed with prostate cancer, and 30-40% of patients who are diagnosed will eventually relapse. But the good news is that more men are being cured of this disease than ever before.
Now in a revised fourth edition, this lifesaving guide by Dr. Patrick Walsh and award-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different... View Details
Prostate Cancer: A New Approach to Treatment and Healing
by Dr. Emilia A. Ripoll (Author), Mark B. Saunders (Author)
Prostate Cancer: A New Approach to Treatment and Healing gives readers new access to leading-edge medical information about prostate cancer, by making it simple and easy-to-understand. Essentially, this is a picture book for adults, written in everyday English, with lots of state-of-the-art information to support all the images, flow charts, tables, and diagrams. Each chapter has a patient story, doctor story, and interactive Toolbox section. The book also contains a Spouses Section (because no one goes through a prostate cancer diagnosis alone) and a Digging Deeper section for readers... View Details
Prostate and Cancer: A Family Guide to Diagnosis, Treatment, and Survival
by Sheldon Marks (Author)
Renowned prostate cancer specialist Sheldon Marks offers the definitive guide for men concerned about or diagnosed with prostate cancer.
Prostate cancer is one of the most common cancers affecting American men, with over 186,000 new cases diagnosed in the United States annually; 1 in 6 men will be diagnosed with prostate cancer during his lifetime.
Since the third edition (2003), there have been significant changes in treatment and resources. Working with Dr. Judd Moul, the Chairman of Urology at Duke and one of the world's top experts on prostate cancer, Marks provides the... View Details
The Key to Prostate Cancer: 30 Experts Explain 15 Stages of Prostate Cancer
by Dr Mark Scholz (Author)
This book directs patients to understand options and educate them about treatments specific for their stage of prostate cancer.
·A short STAGING QUIZ directs patients to their correct stage and which of the seven sections of the book to read.
·The book is divided into seven sections written by experts in prostate cancer. Five of the sections cover the FIVE STAGES OF BLUE.
·The average reader will only need to read three sections: Section I, which covers PSA,Gleason score and body scans, Section VII, which covers lifestyle and general health and... View Details
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer
by Patrick C. Walsh (Author), Janet Farrar Worthington (Author)
Each year, more than 230,000 men are diagnosed with prostate cancer, and 30 to 40 percent of patients who are diagnosed will eventually relapse. But the good news is that more men are being cured of this disease than ever before. Now in a revised third edition, this lifesaving guide by Dr. Patrick Walsh and award-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different disease in every man, which means that the right treatment varies for each man. Readers will discover their risk factors, simple changes that can... View Details
You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It
by Robert J. Marckini (Author)
The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes had been available when he was diagnosed 6 years ago. It is intended to provide specific information for men who are at risk or have been recently diagnosed with prostate cancer. All major treatment... View Details
Prostate Cancer Breakthroughs: The New Options You Need to Know About
by Jay S. Cohen (Author)
"Vital new information for men diagnosed with prostate cancer!"
―George Johnson, Director of the Informed Prostate Cancer Support Group in San Diego, the largest independent group in California
If you or someone you know is one of the thousands of men diagnosed with prostate cancer each year, this book is must reading. In Prostate Cancer Breakthroughs, best-selling author Dr. Jay Cohen provides new information on PSA testing, targeted biopsy, and groundbreaking prostate cancer treatments.
Concise and easy to understand,... View Details
Prostate Cancer: A Man's Guide to Treatment
by Arthur Centeno MD (Author)
More than 200,000 men are diagnosed with prostate cancer annually in the United States. Another 5 million men are living with the disease. The good news is that prostate cancer, when detected early, is very curable. And even when it is not curable, it can still be treated, giving a man many more years of life. Author Arthur Centeno, MD, is a specialist in prostate health and prostate cancer, whounderstands the anxiety that often accompanies a cancer diagnosis. In this comprehensive guide, he answers such questions as: How is prostate cancer diagnosed? What are the surgical treatment options?... View Details
The Prostate Health Diet: What to Eat to Prevent and Heal Prostate Problems Including Prostate Cancer, BPH Enlarged Prostate and Prostatitis
by Ronald M Bazar (Author), Coreen Boucher (Editor)
Do you know the best diet for your prostate gland?
Do you know the best diet for preventing or curing prostate cancer?
Do you know the best diet for your prostate health and to prevent prostate disease?
Most men don’t.
The Prostate Health Diet shows you how to find the best diet for you and how to customize your diet for optimum health and your uniqueness.
The Prostate Health Diet is not a fad diet. It will guide you to find what will work for you with practical insights into the often conflicting views of what you should... View Details
Thrive Don't Only Survive: Dr.Geo's Guide to Living Your Best Life Before & After Prostate Cancer
by Dr. Geo Espinosa (Author)
Prostate cancer is not the end—it’s the beginning. It’s the point where you start taking control.
Information on what to do isn't hard to find. There are dozens of books on prostate cancer, as well as a massive amount of online resources. What's lacking, however, is a trusted, reliable source on implementing the abundance of scientific evidence in a way that’s realistic and sustainable.
Based on his extensive research and clinical experience on natural medicine for prostate problems, Dr. Geo has created a lifestyle blueprint that men can apply immediately to thrive before or... View Details